OYST Oyster Point Pharma, Inc.

Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. Its lead product candidate, OC-01, is a nicotinic acetylcholine receptor agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. The company was founded by Michael and is Ackermann in June 30, 2015 headquartered in Princeton, NJ.

$16.99  -0.79 (-4.44%)
As of 05/10/2021 15:59:53 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  10/31/2019
Outstanding shares:  25,962,144
Average volume:  45,776
Market cap:   $463,164,649
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    69242L106
ISIN:        US69242L1061
Sedol:      BKV26Q2

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   2.71
PS ratio:   0.00
Return on equity:   -42.73%
Net income %:   0.00%